Education
About Us
Working with TipRanks
Follow Us
Tango Therapeutics (TNGX)
NASDAQ:TNGX
TNGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.23 - $12.02
Previous CloseN/A
Volume187.94K
Average Volume (3M)844.82K
Market Cap
$137.30M
Enterprise Value$114.41M
Total Cash (Recent Filing)$69.53M
Total Debt (Recent Filing)$36.49M
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
May 07, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding108,107,890
10 Day Avg. Volume908,123
30 Day Avg. Volume844,820
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.52
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.72
Enterprise Value/Ebitda-0.80
Forecast
1Y Price Target
$11.50Price Target Upside739.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Tango Therapeutics News
PremiumCompany Announcements
Tango Therapeutics Advances Cancer Treatment Pipeline
PremiumCompany Announcements
Tango Therapeutics Highlights Breakthroughs in Cancer Treatment
---
Bulls Say, Bears Say
Bulls Say
Drug EfficacyTNG462 had an objective response rate of 43% in 7 evaluable cholangiocarcinoma patients, which is above the 18% objective response rate for BMY's BMS-504.
Financial PerformanceTNGX reported $257.9mn in cash and cash equivalents, expected to fund operations into 3Q26.
Market SentimentMarket overreaction provides attractive stock price entry point.
Bears Say
Clinical TrialsThe first launch of TNG462 has been delayed by two years to 2028 to more accurately reflect the company's latest clinical trial plans.
Drug SafetySafety suggests minimal adverse effects for the 160/200mg dose, but for the 300mg dose, the rates of thrombocytopenia and anemia were over 30%, above that seen for BMS-504 and AMG193.
Investor SentimentInvestors were disappointed this update contained no numerical TNG462 efficacy data for the remaining evaluable patients, particularly pancreatic and lung which represent larger commercial opportunities.
---
Ownership Overview
50.83% Insiders
12.00% Mutual Funds
0.01% Other Institutional Investors
28.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TNGX FAQ
What was Tango Therapeutics’s price range in the past 12 months?
Tango Therapeutics lowest stock price was $1.23 and its highest was $12.02 in the past 12 months.
What is Tango Therapeutics’s market cap?
Tango Therapeutics’s market cap is $137.30M.
When is Tango Therapeutics’s upcoming earnings report date?
Tango Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 33 days.
How were Tango Therapeutics’s earnings last quarter?
Tango Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.338 by -$0.012.
Is Tango Therapeutics overvalued?
According to Wall Street analysts Tango Therapeutics’s price is currently Undervalued.
Does Tango Therapeutics pay dividends?
Tango Therapeutics does not currently pay dividends.
What is Tango Therapeutics’s EPS estimate?
Tango Therapeutics’s EPS estimate is -0.36.
How many shares outstanding does Tango Therapeutics have?
Tango Therapeutics has 108,107,890 shares outstanding.
What happened to Tango Therapeutics’s price movement after its last earnings report?
Tango Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.338. Following the earnings report the stock price went down -6.438%.
Which hedge fund is a major shareholder of Tango Therapeutics?
Currently, no hedge funds are holding shares in TNGX
---
Tango Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.50 (739.42% Upside)
$11.50 (739.42% Upside)
Blogger Sentiment
Bullish
TNGX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $143.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.46%
12-Months-Change
Fundamentals
Return on Equity
-57.58%
Trailing 12-Months
Asset Growth
-21.03%
Trailing 12-Months
Company Description
Tango Therapeutics
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
---
TNGX Stock 12 Month Forecast
Average Price Target
$11.50
▲(739.42% Upside)
Technical Analysis
Curis
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering TNGX
1 Year
1 Year Success Rate
7/21 ratings generated profit
1 Year Average Return
-11.87%
reiterated a buy rating last month
Copying Andrew Berens's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -11.87% per trade.
---